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I.  Abstract 
 
The major histocompatibility complex (MHC) is a gene family responsible for 
many critical functions of the immune system in most vertebrates.  The MHC 
consists of three classes differentiated by their structure and function, and MHC 
class I encodes antigen binding proteins as well as chaperone and accessory 
proteins such as tapasin.  The purpose of this project is to reconstitute several 
human MHC class I molecules in their peptide-filled and peptide-deficient forms, 
and to purify these proteins for biochemical study.  The expressed proteins 
include wild type and mutant variants of the fusion protein human leukocyte 
antigen HLA-B*0801-fos, and human beta-2-microglobulin (β2m).  The major 
experiments performed for this project include: 1) transformation of engineered 
plasmids into competent cells; 2) large scale protein production; 3) extraction and 
purification of proteins as inclusion bodies; 4) reconstitution of proteins into their 
native structure; 5) purification of refolded proteins.  The purified MHC class I 
molecules can be used to study their interactions with transmembrane chaperone 
and accessory proteins that reside in the endoplasmic reticulum for the purpose 
of better understanding the class I antigen presentation pathway. 
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III. Introduction 
 
The major histocompatibility complex (MHC) is a gene family responsible for 
many critical functions of the immune system in most vertebrates.  The MHC 
consists of three classes differentiated by their structure and function, and MHC 
class I encodes antigen binding proteins as well as chaperone and accessory 
proteins such as tapasin.  The purpose of this project is to reconstitute several 
human MHC class I molecules in their peptide-filled and peptide-deficient forms, 
and to purify these proteins for biochemical study.  Purified MHC class I 
molecules can be used to study their interactions with transmembrane chaperone 
and accessory proteins that reside in the endoplasmic reticulum for the purpose 
of better understanding the class I antigen presentation pathway. 
 
The expressed proteins include wild type and mutant variants of the fusion 
protein human leukocyte antigen HLA-B*0801-fos, and human beta-2-
microglobulin (β2m).  The protein and nucleotide sequences of these genes are 
listed in the appendix, section IX.1.  HLA-B*0801-fos was specifically designed to 
enhance in vitro interactions with tapasin-jun.  Fos and jun interactions between 
these proteins allow the B*0801 and tapasin portions of the proteins to be within 
vicinity of one another, mimicking the environment in the Endoplasmic reticulum.  
β2m is the small subunit of MHC class I molecule, including HLA-B*0801.  
Association with β2m is generally required for the transport of class I heavy 
chains from the endoplasmic reticulum to the cell surface. 
 
Essential interaction regions between HLA-B*0801-fos and tapasin-jun can be 
studied through experiments involving mutant variants of these proteins.  The 
location of these regions can be pinpointed by studying changes in interactions 
between HLA-B*0801-fos and tapasin-jun mutated at specific residues.  
Residues 222, 227 and 229 of the HLA-B*0801 protein are hypothesized to be 
key regions of interaction with tapasin-jun.  The series of experiments performed 
in this project attempted to reconstitute wild type HLA-B*0801fos proteins and 
HLA-B*0801fos proteins mutated at the specific residues 222, 227 and 229.  In 
addition, the experiments attempted to reconstitute β2m proteins of both wild 
type and mutant variety. 
 
The major experiments performed for this project include: 1) transformation of 
engineered plasmids into competent cells; 2) large scale protein production; 3) 
extraction and purification of proteins as inclusion bodies; 4) reconstitution of 
proteins into their native structure; 5) purification of refolded proteins.   
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IV. Experiment 
 
IV.1 Plasmid preparation of PGMT7 with HLA-B*0801fos gene and PLM1 
with β2m gene 
 
Pure plasmid samples of PGMT7 containing the HLA-B*0801fos and PLM1 
containing the β2m gene were extracted from a stock culture of previously 
transformed DH5α cells.  First, the cells were streaked on Luria-Bertani (LB) agar 
plate with ampicillin and incubated overnight at 37°C.  After incubation, cells that 
contained the mutant plasmid formed colonies on the plate.  An isolated colony 
was selected and inoculated into 25ml of 2% LB nutrient broth and grown 
overnight at 30°C. 
 
Pelleted cells were collected from the 25ml culture by centrifugation.  The pellets 
were distributed into five 1.5ml microcentrifuge tubes.  Plasmids were extracted 
from these pelleted cells using the QIAspin miniprep kit from Qiagen.  This 
process yielded about a 500µl solution of pure plasmid.  The plasmid solution 
was concentrated to a final volume of 100µl through vacuum evaporation.  The 
plasmid was stored in a 1.5ml microcentrifuge tube at -20°C. 
 
The final concentration of the plasmid solution was determined through mass 
spectroscopy.  5µl of the solution was mixed with 495µl of sterilized water and 
the optical density at 260nm wavelength (OD260) of the mixture was measured.  
The concentration of the plasmid solution was determined by using the following 
formulas IV.1.1 and IV.2.2. 
 
C (µg/ml) = 50*A*D      (IV.1.1) 
 
C (mM) = 0.15*A*D      (IV.2.2) 
 
C = Concentration  
A = Absorbance =  OD260 of the mixture 
D = Dilution factor = 100
 
 
A total of six plasmid preparations were made: two for wild type HLA-B*0801fos 
and β2m genes, one for a mutant β2m gene, and three for each of the mutant 
HLA-B*0801fos genes “222”, “227”, “229”. 
 
IV.2 Induced substitution mutation of PGMT7 plasmid containing HLA-
B*0801fos and PLM1 plasmid containing β2m gene 
 
Primers were designed to induce mutations in PGMT7 plasmids containing the 
HLA-B*0801fos gene and PLM1 plasmids containing the β2m gene through a 
polymerase chain reaction (PCR).   A total of 4 sets of primers were designed 
according to the QuikChangeTM XL Site Directed Mutagenesis Kit, as shown in 
table IV.2.1.   Three of these sets were used to induce a codon change in the 
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HLA-B*0801fos gene and one was used to induce a codon change in the β2m 
gene.  The primers were synthesized by Tufts University Core Facility. 
 
A set of forward and reverse primers, 125ng each, were combined with 10ng of 
circular plasmid containing the targeted gene into a reaction buffer with 0.0002 M 
Deoxyribonucleotide triphosphate (dNTP) and 1µl of Pfu DNA polymerase, with a 
final volume of 50µl.  Additionally, a control was made, which contained all the 
contents of the experimental mixture except the circular plasmid.  PCR was 
performed by placing the solutions through a heating cycle outlined in Table 
IV.2.2. 
 
Gel electrophoresis was used to check the result of the PCR, using 0.8% 
agarose gel and 5µl of the PCR product.  The remainder of the product was 
stored at -20°C.  Four induced mutation experiments were performed, one for 
each set of primers in table IV.2.1. 
 
Table IV.2.1. Primers for Substitution Mutation 
B8fos222: HLA-B*0801fos Residue 222 Glutamic Acid to Alanine 
mutation 
B8F222 forward primer : 
5’ GGC AGC GGG ATG GCG CGG ACC AAA CTC AGG 3’ 
B8R222 reverse primer: 
5’ CCT GAG TTT GGT CCG CGC CAT CCC GCT GCC 3’ 
 
B8fos227: HLA-B*0801fos Residue 227 Aspartic Acid to Alanine mutation 
B8F227 forward primer: 
5’ GGA CCA AAC TCA GGC CAC TGA GCT TGT GGA 3’ 
B8R227 reverse primer: 
5’ GTC TCC ACA AGC TCA GTG GCC TGA GTT TGG 3’ 
 
B8fos229: HLA-B*0801fos Residue 229 Glutamic Acid to Alanine 
mutation 
B8F229 forward primer: 
5’ CCA AAC TCA GGA CAC TGC GCT TGT GGA GAC 3’ 
B8R229 reverse primer: 
5’ CTG GTC TCC ACA AGC GCA GTG TCC TGA GTT 3’ 
 
β2m58: β2m Residue 58 Lysine to Alanine mutation 
β2mF58 forward primer: 
5’ GTG GAG CAT TCA GAT TTG TCC TTT AGC GCG GAT TGG TCG TTT 
TAT CTC TTG TAC TAC ACT 3’ 
β2mR58 reverse primer: 
5’ CAG TGT AGT ACA AGA GAT AAA ACG ACC AAT CCG CGC TAA AGG 
ACA AAT CTG AAT GCT CCA C 3’ 
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Table IV.2.2. Heating Cycle for Polymerase Chain Reaction  
Temp (°C)  time (s) cycles 
95 60 1 
95 50 
60 50 
68 540 
18 
68 60 1 
 
 
IV.3 Pure plasmid preparation of PGMT7 with mutant HLA-B*0801fos gene 
and PLM1 with mutant β2m gene 
Products from the PCR reaction were treated with 1µl Dpn1 enzyme for two 
hours to break down the circular plasmids containing the wild type gene and to 
join the ends of the linear plasmids containing the specified mutated gene. 
 
After Dpn1 digestion, 10µl of the mutant and control PCR products were added to 
separate microcentrifuge tubes each containing 50ml of thawed DH5α competent 
cells.  In addition, 2.5µl of control puc19 plasmid was added to another 50ml of 
competent cells.  The mixtures were incubated in ice for 30 minutes, followed by 
a 20 second heat shock at 37°C.  After additional 2 minute incubation on ice, 
950µl of LB medium is added to each mixture, followed by additional 1 hour 
incubation at 37°C.  Each of the mixtures were spread on Luria-Bertani plus 
ampicillin (LBA) agar plates with the amount in the table IV.3.1 
 
An isolated colony was selected from either plate 1 or 2 and inoculated into 25ml 
LB nutrient broth and grown overnight at 30°C.  500µl of the culture was 
combined with 15% glycerol and stored at -80°C for future use.  Plasmids were 
extracted from the remaining overnight culture by following the plasmid 
preparation procedures described in section IV.1, and stored at -20°C.  A sample 
of the extracted plasmid was used for DNA sequencing by Tufts University Core 
Facility to check if the mutated gene is present.  Four sets of plasmids were 
created that contained the specified gene and mutation according to table IV.2.1. 
 
Table IV.3.1. LBA Agar Plate Contents for DH5α Transformation 
plate content amount 
1 Mutant 200µl 
2 Mutant 400µl 
3 Control 200µl 
4 Control 400µl 
5 Control puc19 100µl 
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IV.4 Transformation of PGMT7 plasmids with mutant HLA-B*0801fos gene 
and PLM1 plasmids with mutant β2m gene into protein producing 
competent cells  
 
PGMT7 plasmids with mutant HLA-B*0801fos gene were transformed into BL21 
(DE3) competent cells, while PLM1 plasmids with mutant β2m gene were 
transformed into BL21 (DE3) PLysS competent cells. 
 
Two microcentrifuge tubes containing 100µl of thawed competent cells were 
each treated with 1.7µl of β-mercaptoethanol and incubated in ice for 10 minutes.  
Cells from the first tube were transformed with 1µl of plasmid solution containing 
the target mutant gene.  Also, 1µl of puc18 plasmid solution was added to the 
second tube for use as a control.  After additional 30 minute incubation in ice, 
contents in each tube were heat shocked at 42°C for 45 seconds, followed by 2 
minute ice incubation.  The two tubes are then placed in a 37°C incubator for 1 
hour.  Each of the mixtures were spread on LB agar plates containing the 
appropriate antibiotic, and in the amount shown in table IV.4.1.  These plates 
were incubated overnight at 37°C and used for expression test as described in 
section IV.5 
 
Table IV.4.1. LBA Agar Plate Contents for BL21 Transformation 
host strain antibiotics used 
BL21 (DE3) ampicillin 
BL21 (DE3) PLysS ampicillin, chloramphenicol  
 
plate content amount 
1 Mutant 100µl 
2 Mutant 200µl 
3 Control puc18 100µl 
 
IV.5 Protein Expression Test of transformed BL21 (DE3) and BL21 (DE3) 
PLysS cells 
 
5 isolated colonies were selected from either plate 1 or 2 from experiment IV.4 
and inoculated into separate sterile tubes each containing 2ml LBA nutrient broth 
and grown overnight at 30°C.  Afterwards, 50µl was taken from each of these 
cultures and combined with 4.95ml of LB nutrient agar to make 1/100 dilutions.  
The diluted cultures were placed in a shaker set at 37°C for about 3 hours, until 
the contents reached an optical density at 600nm wavelength of OD600 = 0.600.  
300µl were collected from each culture and pelleted cells were separated from 
the supernatant and placed aside in separate 1.5 ml microcentrifuge tubes, and 
stored at -20°C.  Also, 500µl from each tube was collected to create 15% glycerol 
stock cultures for future use.  The remaining cultures were induced with 1mM 
IPTG and returned to the shaker for additional 3 hour incubation.  Another 300ml 
were collected from each tube and the pelleted cells were stored in separate 
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microcentrifuge tubes for SDS gel electrophoresis testing.  The remaining 
cultures were disposed. 
 
The collected cells were each combined with 40µl of loading buffer and boiled at 
100°C for 5 minutes, then centrifuged.  20µl of the supernatant from each tube 
were applied to 12% SDS gel for HLA-B*0801fos, and 15% SDS gel for Β2m.  
For each gel, electrophoresis was conducted for 100 minutes at 130V and 2A.  
The finished gels were stained and used to confirm protein expression of the 
targeted mutant genes. 
 
IV.6 Inclusion body Preparation of mutant HLA-B*0801fos β2m proteins 
 
Cells from a stock culture containing the target gene, made from section IV.5, 
were streaked on an LB agar plate with ampicillin (and chloramphenicol for BL21 
(DE3) PLysS) and incubated overnight.   An isolated colony from the plate was 
selected and inoculated into 50ml LB nutrient broth and grown overnight at 30°C.   
10µl was taken from the culture and added to a flask containing 990ml LB 
nutrient broth and 0.4% glucose to make a 1/100 dilution.  Four of these flasks 
were prepared for a total of 4 liters of culture.  The diluted cultures were placed in 
a shaker set at 37°C for about 3 hours, until the contents reached OD600 = 0.600.  
1ml were collected from each culture and the pelleted cells placed aside in 
separate 1.5ml microcentrifuge tubes and stored at -20°C.  The remaining 
cultures were induced with 1mM IPTG and returned to the shaker for additional 3 
hour incubation.  Another 1000ml were collected from each tube and the pelleted 
cells were stored in separate microcentrifuge tubes for SDS polyacrylamide gel 
electrophoresis (SDS-PAGE).   
 
Pelleted cells were collected from the remaining culture by centrifugation.  The 
cells were then homogenized in 20ml of sucrose solution (table IV.6.1) and then 
lysed by adding 75ml of deoxycholate/triton solution (table IV.6.2)with 30mg of 
lysozyme.  The lysing reaction lasted 20 minutes, at which the solution became 
very viscous.  5mM of magnesium chloride and 5-10mg deoxyribonuclease I was 
added to the solution to break the viscosity. 
 
The solution was frozen using liquid nitrogen and then thawed in warm water, at 
which 1ml of 1M MgCl2 and 1ml 0.5 M EDTA was then added.  All the contents 
were placed into 50ml centrifuge tubes and spun at 8000 rpm and at 4°C for 20 
minutes. 
 
The supernatants were discarded and the pellets were suspended in 40 ml of 
Triton solution (table IV.6.3) and homogenized.  The homogenized mixture was 
once again placed into 50ml centrifuge tubes and spun at 8000 rpm and 4°C for 
20 minutes.  This washing procedure was done three times.  Pellets collected 
after three washes underwent a forth wash following the same procedures except 
that Triton solution was substituted with Tris solution (table IV.6.4). 
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Pellets collected after the forth wash were dissolved and homogenized in 10ml 
Urea solution (table IV.6.5), and then placed into 10 1.5ml microcentrifuge tubes 
and spun at 12000 rpm and at room temperature for 10 minutes.  The 
supernatants were aliquoted into 10 1.5 ml microcentrifuge tubes and frozen at -
80°C. 
 
Bradford assay was used to determine the concentration of the collected 
inclusion bodies.  A standard absorbance versus concentration curve was 
created using stock 2 mg/ml bovine serum albumin (BSA) with the dilutions 
outlined in table IV.6.6.  100ul of each dilution was added to 5ml of 20% Bradford 
dye and the OD at 595nm wavelength was measured.  This curve was used to 
calculate the unknown concentration of the inclusion bodies based on its 
measurable OD and known dilution factor. 
 
Table IV.6.1. Sucrose Solution 
reagent Concentration 
Tris pH 8.0 50mM 
sucrose 25% 
EDTA 1mM 
Sodium Azide 0.10% 
 
Table IV.6.2. Deoxycholate/triton Solution 
reagent Concentration 
Deoxycholate 1% 
Triton x100 1% 
Tris pH7.5 20mM 
Sodium Chloride 0.1M 
Sodium Azide 0.10% 
 
Table IV.6.3. Triton Solution 
reagent Concentration 
Triton x100 0.50% 
Tris 50mM 
Sodium Chloride 100mM 
EDTA 1mM 
Sodium Azide 0.10% 
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Table IV.6.4. Tris Solution 
reagent Concentration 
Tris 50mM 
EDTA 1mM 
Sodium Azide 0.10% 
 
Table IV.6.5. 8M Urea Solution 
reagent Concentration 
Urea 8M 
MES pH6 25mM 
EDTA 1mM 
DTT 0.1mM 
 
Table IV.6.6. Bradford Assay Standard Dilutions 
Concentration 0mg/ml 0.2mg/ml 0.4mg/ml 0.6mg/ml 0.8mg/ml 
BSA (2mg/ml) 0µl 50µl 100µl 150µl 200µl 
8M Urea 500µl 450µl 400µl 350µl 300µl 
 
IV.7 Refolding HLA-B*0801fos Inclusion Bodies 
 
Table IV.7.1 lists the components in the refolding buffer that was used to refold 
the inclusion bodies into their native structure.  First, 2µm of Β2m inclusion was 
added to the refolding buffer, followed by 10mg of synthetic peptide dissolved in 
100ml DMSO, and finally 1µm of the HLA-B*0801fos heavy chain. 
 
The mixture was stored at 4°C for 48 hours, and then placed in 10000 MWCO 
dialysis bags, which were placed in 10L 20mM Tris dialysis buffer (table IV.7.2).  
The dialysis procedure lasted 24 hours, at which then concentration procedures 
began. 
 
Contents from the dialysis bags were concentrated to a volume of 15-30ml using 
the Stir Cell apparatus, using 10000 MWCO membranes.  The contents from the 
Stir Cell were then placed in 1-2 Centripreps and concentrated to a final volume 
of about 1ml and placed in a 1.5ml microcentrifuge tubes and spun at 12000 rpm 
and at 4°C for 30 minutes.  The supernatant, which contained refolded HLA-
B*0801fos and β2m, were transferred to another clean 1.5ml microcentrifuge 
tube. 
 
Refolded HLA-B*0801fos and β2m were each separated from aggregates and 
other unwanted items according to their mass by using a fast protein liquid 
chromatography (FPLC) system.  The collected purified HLA-B*0801fos and β2m 
were placed into a 10000 MWCO and a 3000 MWCO Centriprep, respectively, 
and each concentrated to 1ml. 
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The final concentrations of the samples were determined using mass 
spectroscopy.  5µl from a sample was combined with 600µl of 6M Guanidine 
Hydrochloride and stored at room temperature for one hour.  The OD of this 
mixture was measured and used to calculate the concentration of the sample 
using formulas IV.7.1 and IV.7.2. 
 
C(M) = A/E*D       (IV.7.1) 
C(mg/ml) = A/E*D*MW      (IV.7.2) 
 
C = concentration 
A = absorbance = OD280 
D = dilution factor = 605/5 
MW HLA-B*0801fos = 50080kDa 
MW β2m = 11400kDa 
 
Table IV.7.1. 1L Refolding Buffer 
reagent Concentration (mM) Comments 
Tris pH 8 50mM 50 ml added from 1M stock 
Arginine pH8 400mM 200 ml added from 200ml stock (filtered) 
EDTA pH 8 1mM 2ml added from stock 0.5M 
GSSH 0.5mM 1.5g added directly 
GSSG 0.5mM 0.38g added direclty 
PMSF 0.5mM 2.5ml of 200mM fresh stock added 
Water   add up to 1L 
 
Table IV.7.2. 20mM Tris buffer 
reagent Concentration (mM) 
Tris pH 8 20mM 
Sodium Chloride  150mM 
 
IV.8 Creating peptide-less HLA-B*0801fos proteins 
 
From IV.7, 500µl of refolded HLA-B*0801fos was denatured in 1500µl of 8M 
Guanidine Hydrochloride (table IV.8.1) and stored at room temperature for 4 
hours.  The HLA-B*0801fos heavy chain was separated from Β2m using the 
FPLC with 6M Guanidine Hydrochloride gel filtration buffer.  The collected HLA-
B*0801fos was combined with the collected β2m and additional β2m from other 
sources, if necessary, such that the molar ratio is 1:2 Heavy chain to β2m.   
 
The mixture was diluted with 6M Guanidine Hydrochloride (table IV.8.2) to a 
concentration of 1mg HLA-B*0801fos per 1ml, and placed in 3000 MWCO 
dialysis bags and dialyzed against 1L of 8M Urea buffer (table IV.8.3) for 24 
hours at 15°C.  The dialysis buffer was then changed to 1L of 20mM Tris (table 
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IV.7.2) plus 10% Glycerol for 16 hours, at which then the buffer was replaced 
with another 1L of 20mM Tris plus 10% Glycerol.  This process was done for 48 
hours and 3 1L 20mM Tris plus 10% Glycerol buffers were used.   
 
The dialyzed contents were concentrated to 30 ml using a Stir Cell and then to 
1ml using a Centriprep.  Pure peptide-less folded HLA-B*0801fos was collected 
from the concentrated sample using the FPLC with 20mM Tris gel filtration buffer, 
followed by a final Centriprep concentration to 1ml.   The final concentration of 
the sample was determined using mass spectroscopy as described in IV.7 
 
Table IV.8.1. 8M Guanidine Hydrochloride  
reagent Concentration 
Guanidine Hydrochloride 8M 
Sodium Chloride 150mM 
Tris pH 7.5 20mM 
Table IV.8.2. 6M Guanidine Hydrochloride  
reagent Concentration 
Guanidine Hydrochloride 6M 
Sodium Chloride 150mM 
Tris pH 7.5 20mM 
 
Table IV.8.3. 8M Urea Buffer 
reagent Concentration 
Urea 8M 
MES pH6 25mM 
EDTA 1mM 
DTT 0.1mM 
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V. Results and Discussion 
 
V.1 Plasmid preparation of PGMT7 with HLA-B*0801fos gene and PLM1 
with β2m gene 
 
The final concentration of the PGTM7 plasmid solution with HLA-B*0801fos gene 
was 380 µg/ml and was sufficient for further PCR experiments.  Absorbance for 
the solution was low at OD260 = 0.076 and a lower dilution factor can be used to 
increase this value to be in the range of 0.1 – 0.9.  An increase in plasmid yield 
can be obtained by increasing the amount of cell culture used. 
 
V.2 Induced substitution mutation of PGMT7 plasmid containing HLA-
B*0801fos and PLM1 plasmid containing β2m gene 
 
Gel electrophoresis results of several PCR mutation reaction products are shown 
in figures V.2.1 – V.2.3.  PCR results with B8fos222 primers (figure V.2.1) were 
somewhat inconclusive as the bands for control (lane 4) and mutant (lane 5) 
were quite faint and can only be seen under careful inspection of the gel itself.  
The photograph of the gel renders these bands invisible.  These results indicated 
that 5µl of sample may not be enough.  For PCR reactions using B8fos227, 
B8fos229 and β2m58 primers, 10µl of the products were used for gel 
electrophoresis, which produced much better clarity, as shown by figures V.2.2 – 
V.2.4..  Despite the lack of clarity of the 222 gel, the results confirm that the PCR 
reactions were successful. 
 
 
Figure V.2.1. PCR results with B8fos222 primers.  Starting from the left, lanes 1 
and 3 are makers, lane 4 is control and lane 5 is the mutant.  Lane 4 contains no 
bands near 30kb, which shows that PCR did not occur for the control.  Although 
not visible in this photo, a faint band is present in lane 5 at the location indicated 
by the arrow near 30kb, showing that the PCR reaction was successful and that 
the plasmids were produced. 
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Figure V.2.2. PCR results with B8fos227 primers.  Starting from the left, lane 1 is 
a maker, lane 3 is the mutant and lane 6 is the control.  Lane 3 contains only one 
band at around 30kb, which suggests that all the primers were used up to create 
mutant plasmids.  Lane 6 contains a strong band near 50b, which represents 
unused 227 primers. 
 
 
 
Figure V.2.3. PCR results with B8fos229 primers. Starting from the left, lane 1 is 
a maker, lane 3 is the mutant and lane 5 is the control.  A band at around 30kb, 
suggests that the PCR reaction was successful and plasmids were replicated.  
Lane 5 contains a strong band near 50b, which represents unused 229 primers. 
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Figure V.2.4. PCR results with β2m58 primers. Starting from the left, lane 1 is a 
maker, lane 2 is the mutant and lane 3 is the control.  A band at around 30kb for 
lane 1 suggests that the PCR reaction was successful and plasmids were 
replicated.   
 
 
V.3 Pure plasmid preparation of PGMT7 with mutant HLA-B*0801fos gene 
and PLM1 with mutant β2m gene 
 
The transformation results for each plasmid were expected.  Colony growth was 
observed in LBA agar plates with competent cells strains transformed with a 
mutant sample from PCR or the control puc19 plasmid.  Cells transformed with a 
control sample from PCR did not form colonies on LBA agar plates. 
 
The sequencing results each plasmid are in Appendix – IX.3.  The results show 
that induced mutation using primers B8fos222, B8fos227, and B8fos229 were 
successful and produced the specified point mutation.  However, the first β2m 
mutation was unsuccessful as the sequencing results show a combination of 
insertion and frameshift mutations in the β2m gene, as opposed to the expected 
point substitution mutation.  The original set of primers (see Appendix – IX.2) had 
a melting temperature slightly lower than the recommended values according to 
the QuikChangeTM XL Site Directed Mutagenesis Kit and was also relatively short 
compared to the primers B8fos222, B8fos227 and B8fos229.  A second set of 
primers were designed to carry out the β2m mutation and is listed in table IV.2.1.  
This primer set was significantly longer than the first set and induces additional 
point mutations, but the codons remain unchanged.   Sequencing results 
indicates that PCR using this primer yielded the expected point mutation in the 
β2m gene contained in the PLM1 plasmid. 
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V.4 Transformation of PGMT7 plasmids with mutant HLA-B*0801fos gene 
and PLM1 plasmids with mutant β2m gene into protein producing 
competent cells  
 
The transformation results for each plasmid were expected.  Colony growth was 
observed in LBA or LBAC agar plates with competent cells strains transformed 
with a mutant sample from PCR or the control puc18 plasmid.  Cells transformed 
with a control sample from PCR did not form colonies on LBA or LBAC agar 
plates.   
 
V.5 Protein Expression Test of transformed BL21 (DE3) and BL21 (DE3) 
PLysS cells 
 
SDS-PAGE results of several expression tests are shown in figures V.6.1 – 
V.6.3.  Leaked expression was observed for expression tests for the BL21 (DE3) 
strain transformed with PGMT7 plasmids containing the B8fos222, B8fos227, 
B8fos229 mutations.  This problem was not observed in the expression test done 
with the BL21 (DE3) PLysS strain transformed with PLM1 plasmids containing 
the β2m58 mutation.  Despite leaked expression, the results confirmed that the 
transformed cells produced the specified proteins. 
 
 
Figure V.5.1. SDS-PAGE result of B8fos222 expression test.  Starting from the 
left, lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.  
Lanes 3,5,7,9 are cells after induction.  Dominant bands near 35 kDa suggested 
that HLA-B*0801fos proteins were produced. 
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Figure V.5.2. SDS-PAGE result of B8fos227 expression test.  Starting from the 
left, lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.  
Lanes 3,5,7,9 are cells after induction.  Bands near 35 kDa suggested that HLA-
B*0801fos proteins were produced, although large amounts of other proteins 
were produced as well. 
 
 
Figure V.5.3. SDS-PAGE result of B8fos229 expression test.  Starting from the 
left, lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.  
Lanes 3,5,7,9 are cells after induction.  Dominant bands near 35 kDa suggested 
that HLA-B*0801fos proteins were produced. 
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Figure V.5.4. SDS-PAGE result of β2m58 expression test.  Starting from the left, 
lane 1 is a maker, lanes 2,4,6,8 are cells contents before IPTG induction.  Lanes 
3,5,7,9 are cells after induction.  Dominant bands near 16 kDa for lanes 3,5,7,9 
suggested that HLA-B*0801fos proteins were produced.  The use of BL21 (DE3) 
PLysS cell line may have prevented leaked expression. 
 
V.6 Inclusion body Preparation of mutant HLA-B*0801fos β2m proteins 
 
SDS-PAGE results of the inclusion bodies are shown in figures V.6.1 – V.6.3.  
For HLA-B*0801fos, lanes that have a large band near 36 kDa compared with 
other relatively weak bands shows that the inclusion body preparations contained 
mostly HLA-B*0801fos protein and small amounts of other proteins.  A large 
band near 16 kDa for β2m also confirms that the inclusion body preparation 
contained mostly β2m proteins.   
 
Figure V.6.1. SDS-PAGE result of B8fos222 inclusion bodies.  Lanes 4,5,6,7 are 
inclusion body samples after each subsequent wash, with lane 4 being after the 
first wash.  The dominant bands observed at these lanes are near 36 kDa. 
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Figure V.6.2. SDS-PAGE result of B8fos227 inclusion bodies.  Lanes 4,5,6,7 are 
inclusion body samples after each subsequent wash, with lane 4 being after the 
first wash.  The dominant bands observed at these lanes are near 36 kDa. 
 
Figure V.6.3. SDS-PAGE result of B8fos229 inclusion bodies.  Lanes 4,5,6,7 are 
inclusion body samples after each subsequent wash, with lane 4 being after the 
first wash.  Lane 3 contains inclusion body sample before any wash.  The 
dominant bands observed at these lanes are near 36 kDa. 
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Figure V.6.4. SDS-PAGE result of β2m58 inclusion bodies.  Lanes 4,5,6,7 are 
inclusion body samples after each subsequent wash, with lane 4 being after the 
first wash.  Lane 3 contains inclusion body sample before any wash.  The 
dominant bands observed towards the bottom of these lanes are near 16 kDa. 
 
V.7 Refolding HLA-B*0801fos Inclusion Bodies 
 
Chromatograph results from FPLC purification of HLA-B*0801fos proteins are 
shown in Figure V.7.1.  Generally, the HLA-B*0801fos peak is at 29 minutes, 
followed by excess β2m proteins at 38 minutes.  The aggregate peak at 18 
minutes varies in strength depending on the concentration of the sample.  A high 
concentration usually resulted in a high aggregate peak (figure V.7.1) whereas a 
low concentration yielded a low peak (figure V.7.2). 
 
 
Figure V.7.1. Chromatograph of FPLC purification of HLA-B*0801fos proteins.  A 
1L refold was concentrated to 500ml before purification.  The high concentration 
lead to a large aggregate peak. 
 
 21 
 
Figure V.7.2. Chromatograph of FPLC purification of HLA-B*0801fos proteins.  A 
1L refold was concentrated to 5ml before purification.  The low concentration 
significantly reduced the aggregate peak and lead to a larger HLA-B*0801fos 
peak. 
 
V.8 Creating peptide-less HLA-B*0801fos Proteins 
Chromatograph results from FPLC purification of denatured HLA-B*0801fos 
proteins are shown in Figure V.8.1, and results from FPLC purification of refolded 
peptide-less HLA-B*0801fos proteins are shown in Figure V.8.2.  Aggregates are 
almost undetectable by these chromatographs as they have been removed from 
previous purifications.  
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Figure V.8.1. Chromatograph of FPLC purification of denatured HLA-B*0801fos 
proteins.  The first large peak represents denatured HLA-B*0801fos and the 
second peak represents denatured β2m 
 
 
Figure V.8.2. Chromatograph of FPLC purification of peptide-less HLA-
B*0801fos proteins.  The first large peak represents peptide-less HLA-B*0801fos 
proteins and the second peak represents excess refolded β2m. 
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VI. Conclusion 
 
Inclusion body preparation of mutant HLA-B*0801-fos and β2m was successful, 
as well as the reconstitution of wild type HLA-B*0801-fos protein in both peptide-
filled and peptide deficient forms.  Several unexpected problems occurred during 
the series of experiments.  First, the first set of mutations that involved the β2m 
primers in IX.1.2 did not produce the desired codon change.  As a result, the 
primers were redesigned and the second mutation attempt produced the 
expected results.  Second, an unusual amount of aggregates were formed in the 
refolding process for HLA-B*0801-fos.  This problem was overcome by 
decreasing the concentration at which the sample was purified.  Other than these 
minor problems, the experiments proceeded as expected and yielded acceptable 
results. 
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IX. Appendix 
 
IX.1 DNA sequences of HLA-B*0801fos gene and β2m gene 
 
IX.1.1 Human Leukocyte Antigen HLA-B*0801fos 
 
         1 atgctggtca tggcgccccg aaccgtcctc ctgctgctct cggcggccct ggccctgacc 
       61 gagacctggg ccggctccca ctccatgagg tatttcgaca ccgccatgtc ccggcccggc 
      121 cgcggggagc cccgcttcat ctcagtgggc tacgtggacg acacgcagtt cgtgaggttc 
      181 gacagcgacg ccgcgagtcc gagagaggag ccgcgggcgc cgtggataga gcaggagggg 
      241 ccggagtatt gggaccggaa cacacagatc ttcaagacca acacacagac tgaccgagag 
      301 agcctgcgga acctgcgcgg ctactacaac cagagcgagg ccgggtctca caccctccag 
      361 agcatgtacg gctgcgacgt ggggccggac gggcgcctcc tccgcgggca taaccagtac 
      421 gcctacgacg gcaaggatta catcgccctg aacgaggacc tgcgctcctg gaccgcggcg 
      481 gacaccgcgg ctcagatcac ccagcgcaag tgggaggcgg cccgtgtggc ggagcaggac 
      541 agagcctacc tggagggcac gtgcgtggag tggctccgca gatacctgga gaacgggaag 
      601 gacacgctgg agcgcgcgga ccccccaaag acacacgtga cccaccaccc catctctgac 
      661 catgaggcca ccctgaggtg ctgggccctg ggcttctacc ctgcggagat cacactgacc 
      721 tggcagcggg atggcgagga ccaaactcag gacactgagc ttgtggagac cagaccagca 
      781 ggagatagaa ccttccagaa gtgggcagct gtggtggtgc cttctggaga agagcagaga 
      841 tacacatgcc atgtacagca tgaggggctg ccgaagcccc tcaccctgag atgggagccg 
      901 tcttcccagt ccaccgtccc catcgtgggc attgttgctg gcctggctgt cctagcagtt 
      961 gtggtcatcg gagctgtggt cgctgctgtg atgtgtagga ggaagagctc aggtggaaaa 
     1021 ggagggagct actctcaggc tgcgtgcagc gacagtgccc agggctctga tgtgtctctc 
     1081 acagcttga 
/translation=MLVMAPRTVLLLLSAALALTETWA 
GSHSMRYFDTAMSRPGRGEP                
RFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIFKTNTQTDRESL                    
RNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHNQYAYDGKDYIALNEDLRSWTAA                     
DTAAQITQRKWEAARVAEQDRAYLEGTCVEWLRRYLENGKDTLERADPPKTHVTHHPI                   
SDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSG                     
EEQRYTCHVQHEGLPKPLTLRWEPSSQSTVPIVGIVAGLAVLAVVVIGAVVAAVMCRR 
                     KSSGGKGGSYSQAACSDSAQGSDVSLTA 
 
Soluble domain of B0801 Heavy chain 
GSHSMRYFDTAMSRPGRGEP      
RFISVGYVDDTQFVRFDSDAASPREEPRAPWIEQEGPEYWDRNTQIFKTNTQTDRESL                    
RNLRGYYNQSEAGSHTLQSMYGCDVGPDGRLLRGHNQYAYDGKDYIALNEDLRSWTAA                     
DTAAQITQRKWEAARVAEQDRAYLEGTCVEWLRRYLENGKDTLERADPPKTHVTHHPI                   
SDHEATLRCWALGFYPAEITLTWQRDGEDQTQDTELVETRPAGDRTFQKWAAVVVPSG                     
EEQRYTCHVQHEGLPKPLTLRWE 
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IX.1.2 Human beta-2-microglobulin (β2m) 
iqrtpkiqvy srhpaengks nflncyvsgf hpsdievdll kngeriekve hsdlsfskdw sfyllyytef 
tptekdeyac rvnhvtlsqp kivkwdrdm   
 (Ribosome binding site) (atg)       
61 atccagcgta ctccaaagat tcaggtttac tcacgtcatc cagcagagaa tggaaagtca       
121 aatttcctga attgctatgt gtctgggttt catccatccg acattgaagt tgacttactg      
181 aagaatggag agagaattga aaaagtggag cattcagact tgtctttcag caaggactgg       
241 tctttctatc tcttgtacta cactgaattc acccccactg aaaaagatga gtatgcctgc       
301 cgtgtgaacc atgtgacttt gtcacagccc aagatagtta agtgggatcg agacatgtaa  
  
Ribosome binding site = aag gag gat att aaa   
 
IX.2 Original B2m primers 
 
β2m58: β2m Residue 58 Lysine to Alanine mutation 
β2mF58 forward primer: 
5’ CAG ACT TGT CTT TCA GCG CGG ACT GGT CTT TCT ATC TC 3’ 
β2mR58 reverse primer: 
5’ GAG ATA GAA AGA CCA GTC CGC GCT GAA AGA CAA GTC TG 3’ 
 
IX.3 Plasmid sequencing results of mutant PGMT7 and β2m from TUFTS 
University Core Facility in FASTA format 
 
>B82221-B44-2 
NgcgGcggAaCCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGAgC
AGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAACG
GGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGACACACGTGACCCACCACCCCATCT
CTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACACT
GACCTGGCAGCGGGATGGCGCGGACCAAACTCAGGACACTGAGCTTGTGGAGACCAGACC
AGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAGCA
GAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGGA
GGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAACTGATACACTCCAAGCGGAGACA
GATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGAGATTGCCAATCTACTGAAAGAGAA
GGAAAAACTGGAGTTCATCCTGGCCGCCCATTAAAAGCTTGAATTCCGATCCGGCTGCTAAC
AAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCC
TTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATAA
TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTAT
TTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATA
ATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCGA
AATCGGCAAAATCCCTTATAAATCAAAAGAATAGACCNANNTAGGGGTTNANNN 
 
>B82221-B44-1 
AGCgcagGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGTACTGgTTaTGCCCG
CGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCTGGAGGGTGTGAGA
CCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCTCTCGGTCAGTCTGT
GTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCCTCCTGCTCTATCCA
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CGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGTCGAACCTCACGAACTGCGT
GTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGGGCCGGGACATGG
CGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGTATATCTCCTTCTTAAAGTTAAACAA
AATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGGGAT
CGAGATCCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCC
GGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGG
AGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATTGCGG
TGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTC
GCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGNATCAGCTCACTCAAA
GGCGGTANTACNGGTTATCCACAGAATCNGGGGANNACGCAGNAAAGAACATGTGAGCAAA
NNNNGCAAAANGCNAGNAANCGTAAAAAGGCCNCGTNGCTGGNGTTTTTNCNNNAGGNNTC
CNNNCCCCNNN 
 
>B82221-T7 
CcTCTagaataaTTTTGTTTAACTTTAAGAAGGAGATATACATATGGGATCCCACTCCATGAGGT
ATTTCGACACCGCCATGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCT
ACGTGGACGACACGCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGC
CGCGGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCT
TCAAGACCAACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCA
GAGCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACG
GGCGCCTCCTCCGCGGGCATAACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAA
CGAGGACCTGCGCTCCTGGACCGCGGCGGACACCGCGGCTCAGATCACCCAGCGCAAGTG
GGAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGT
GGCTCCGCAGATACCTGGAGAACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGA
CACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGG
GCTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGCGGACCAAACTCAGG
ACACTGAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGT
GGTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCC
GAAGCCCCTCACCCTGAGATGGGAGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTT
AACTGATACACTCCAAGCGGAGACAGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACC
GAGATTGCCAATCTACTGAAAGAGAANGGAAAAACTGGGANTTCATCCNGNNNNCCCATTAA
AAGCTNGAATTCCGATNCNGCNGNNTAACAANGCCCCGN 
 
>B82221-T7-Term 
cttcttTCGGGCTTTGTTAGCAGCCGGATCGGAATTCAAGCTTTTAATGGGCGGCCAGGATGAA
CTCCAGTTTTTCCTTCTCTTTCAGTAGATTGGCAATCTCGGTCTGCAACGCAGACTTCTCGTC
TTCAAGTTGATCTGTCTCCGCTTGGAGTGTATCAGTTAACGAGCCACGCGGAACCAGACCG
CCGGAACCTCCCTCCCATCTCAGGGTGAGGGGCTTCGGCAGCCCCTCATGCTGTACATGGC
ATGTGTATCTCTGCTCTTCTCCAGAAGGCACCACCACAGCTGCCCACTTCTGGAAGGTTCTA
TCTCCTGCTGGTCTGGTCTCCACAAGCTCAGTGTCCTGAGTTTGGTCCGCGCCATCCCGCT
GCCAGGTCAGTGTGATCTCCGCAGGGTAGAAGCCCAGGGCCCAGCACCTCAGGGTGGCCT
CATGGTCAGAGATGGGGTGGTGGGTCACGTGTGTCTTTGGGGGGTCCGCGCGCTCCAGCG
TGTCCTTCCCGTTCTCCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAGGC
TCTGTCCTGCTCCGCCACACGGGCCGCCTCCCACTTGCGCTGGGTGATCTGAGCCGCGGT
GTCCGCCGCGGTCCAGGAGCGCAGGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTA
GGCGTACTGGTTATGCCCGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACAT
GCTCTGGAGGGTGTGAGACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAG
GCTCTCTCGGTCAGTCTGTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCG
GCCCCTCCTGCTCTATCCACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGT
CGAACCTCACGAACTGCGTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGC
GGCCGGGCCGGGACATGGCGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGNNNNT
CNNCCNNNN 
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>B82271-B44-2 
gacgCGGCGgAcaCCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGG
AGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGA
ACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGACACACGTGACCCACCACCCCA
TCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCAC
ACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGCCACTGAGCTTGTGGAGACCAG
ACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAG
CAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGG
AGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAACTGATACACTCCAAGCGGAGAC
AGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGAGATTGCCAATCTACTGAAAGAGA
AGGAAAAACTGGAGTTCATCCTGGCCGCCCATTAAAAGCTTGAATTCCGATCCGGCTGCTAA
CAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCC
CTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATA
ATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAA
TGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA
TTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAAT
AATATTTTGTTAAAATTCGCGTTAAATTTTTTGTTAAATCAGCTCATTTTTTTAACCAATAGGCC
GAAATCGGCAAAATCCCTTTATAAATCAAAAAGAATAGACCGANATAGGGGTTNNNNNGNTN
NNTNCCNNNNGNNNCANNNNCCACTATTNAAAGNAANNNNNNNNCNTNCCAANNNNCNAAN
NGGGGNNAAAAAAANCNNNNNNN 
 
>B82271-B44-1 
ggAGCGcAgGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGTACTGgTTATGCC
CGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCTGGAGGGTGTGA
GACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCTCTCGGTCAGTCT
GTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCCTCCTGCTCTATC
CACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGTCGAACCTCACGAACTGC
GTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGGGCCGGGACAT
GGCGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGTATATCTCCTTCTTAAAGTTAAA
CAAAATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGG
GATCGAGATCCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCT
CCCGGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGGGAGCAGACAAGCCCGTCAGGG
CGCGTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAG
CGGAGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATTG
CGGTGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTT
CCTCGCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTC
AAAGGCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCA
AAAGGCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTCCATAGGC
TCCGCCCCCCTGACGANCATCACAAAAATCGACGCTCAANNCAGAGGTGNNNAAACCCGAC
NGGGNNNANNAGATACCAGGNGTTTCCCCCNNNNNNCTCCCTCNNNGCGNNNNNNNCNNN
NCNNAACCCNNNNN 
 
>B82271-T7 
TctagaataATTTTGTTTAACTTTAAGAAGGAGATATACATATGGGATCCCACTCCATGAGGTATT
TCGACACCGCCATGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACG
TGGACGACACGCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGCCGC
GGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCTTCA
AGACCAACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCAGA
GCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACGGG
CGCCTCCTCCGCGGGCATAACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAACG
AGGACCTGCGCTCCTGGACCGCGGCGGACACCGCGGCTCAGATCACCCAGCGCAAGTGG
GAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTG
GCTCCGCAGATACCTGGAGAACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGAC
ACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGC
CACTGAGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTG
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GTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGA
AGCCCCTCACCCTGAGATGGGAGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAA
CTGATACACTCCAAGCGGAGACAGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGA
GATTGCCAATCTACTGAAAGAGAAGGAAAAACTGGNNTTCATCCTGNNNGCCCATTAAAAGC
TTGAANTTCCGATCCNGGCNNCTAACAAANNCCNAAAAGGNANNNNNNNTTNGGGCNNCNN
CCCANCCNNNNNANNNAATNACNNNNNNNTNNNNNCCNNGNGGNNNNNNNNNNNAANNNN
NN 
 
>B82271-T7-Term 
cttcTTTCGGGCTTTGTTAGCAGCCGGATCGGAATTCAAGCTTTTAATGGGCGGCCAGGATGA
ACTCCAGTTTTTCCTTCTCTTTCAGTAGATTGGCAATCTCGGTCTGCAACGCAGACTTCTCGT
CTTCAAGTTGATCTGTCTCCGCTTGGAGTGTATCAGTTAACGAGCCACGCGGAACCAGACC
GCCGGAACCTCCCTCCCATCTCAGGGTGAGGGGCTTCGGCAGCCCCTCATGCTGTACATG
GCATGTGTATCTCTGCTCTTCTCCAGAAGGCACCACCACAGCTGCCCACTTCTGGAAGGTTC
TATCTCCTGCTGGTCTGGTCTCCACAAGCTCAGTGGCCTGAGTTTGGTCCTCGCCATCCCG
CTGCCAGGTCAGTGTGATCTCCGCAGGGTAGAAGCCCAGGGCCCAGCACCTCAGGGTGGC
CTCATGGTCAGAGATGGGGTGGTGGGTCACGTGTGTCTTTGGGGGGTCCGCGCGCTCCAG
CGTGTCCTTCCCGTTCTCCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAG
GCTCTGTCCTGCTCCGCCACACGGGCCGCCTCCCACTTGCGCTGGGTGATCTGAGCCGCG
GTGTCCGCCGCGGTCCAGGAGCGCAGGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCG
TAGGCGTACTGGTTATGCCCGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTAC
ATGCTCTGGAGGGTGTGAGACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGC
AGGCTCTCTCGGTCAGTCTGTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTC
CGGCCCCTCCTGCTCTATCCACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCT
GTCGAACCTCACGAACTGCGTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCC
GCGGCCGGGCCGGGACATGGCGGNGTCGAAATACCTCATGGNNNNNNTCCCATATGNNTA
TCTCCTTNTNANNNNAAACAAAANTNATTTCNANNNGGNNAACCNNNNNNNNNNNNNCCCTN
NNNNNNGNANNNCNNNNNNTNNAANTTTNN 
 
>B82291-B44-1 
gAGcgcagGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGTACTGGTTATGCCCG
CGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCTGGAGGGTGTGAGA
CCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCTCTCGGTCAGTCTGT
GTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCCTCCTGCTCTATCCA
CGGCGCCCGCGGCTCCTCTCTCGGACTCGCGGCGTCGCTGTCGAACCTCACGAACTGCGT
GTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGGGCCGGGACATGG
CGGTGTCGAAATACCTCATGGAGTGGGATCCCATATGTATATCTCCTTCTTAAAGTTAAACAA
AATTATTTCTAGAGGGAAACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCGGGAT
CGAGATCCTGCCTCGCGCGTTTCGGTGATGACGGTGAAAACCTCTGACACATGCAGCTCCC
GGAGACGGTCACAGCTTGTCTGTAAGCGGATGCCGTGAGCAGACAAGCCCGTCAGGGCGC
GTCAGCGGGTGTTGGCGGGTGTCGGGGCGCAGCCATGACCCAGTCACGTAGCGATAGCGG
AGTGTATACTGGCTTAACTATGCGGCATCAGAGCAGATTGTACTGAGAGTGCACCATTGCGG
TGTGAAATACCGCACAGATGCGTAAGGAGAAAATACCGCATCAGGCGCTCTTCCGCTTCCTC
GCTCACTGACTCGCTGCGCTCGGTCGTTCGGCTGCGGCGAGCGGTATCAGCTCACTCAAAG
GCGGTAATACGGTTATCCACAGAATCAGGGGATAACGCAGGAAAGAACATGTGAGCAAAAG
GCCAGCAAAAGGCCAGGAACCGTAAAAAGGCCGCGTTGCTGGCGTTTTTTNCATAGGCTCC
GCCCCCCCTGACGAGCATCACAAAAATCGACGCTCAAGNCAGANGGTGGCGAAACCCGAC
NGGNNTATAAAGAATACCAGGGNNNNNNCCCCCCNN 
 
>B82291-B44-2 
gaCGcggcGgAcaCCGCGGCTCAGATCACCCAGCGCAAGTGGGAGGCGGCCCGTGTGGCGGa
gCAgGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTGGCTCCGCAGATACCTGGAGAA
CGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGACACACGTGACCCACCACCCCAT
CTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGGCTTCTACCCTGCGGAGATCACA
CTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGACACTGCGCTTGTGGAGACCAGA
CCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTGGTGGTGCCTTCTGGAGAAGAG
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CAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGAAGCCCCTCACCCTGAGATGGG
AGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAACTGATACACTCCAAGCGGAGAC
AGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGACCGAGATTGCCAATCTACTGAAAGAGA
AGGAAAAACTGGAGTTCATCCTGGCCGCCCATTAAAAGCTTGAATTCCGATCCGGCTGCTAA
CAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCC
CTTGGGGCCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATA
ATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAA
TGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTA
TTTTTCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAAT
AATATTTTGTTAAAATTCGCGTTAAATTTTTGTTAAATCAGCTCATTTTTTAACCAATAGGCCG
AAATCGGCAAAANCCCTTATAAATCAAAAGAATAGACCGNNATAGGGTTGANTGNNGTTNCN
NNTTNGNNNCNNGANTCCCNCTANTNAAGANNNNNNTCNNCNNNCAAGNNNNAAAAANCNN
CNNTCNNGNNNNNNNNNNCNNNCNNNNNNNNNNNN 
 
>B82291-T7 
tctagaatAATTTTgTTTAACTTTAAGAAGGAGATATACATATGGGATCCCACTCCATGAGGTATTT
CGACACCGCCATGTCCCGGCCCGGCCGCGGGGAGCCCCGCTTCATCTCAGTGGGCTACGT
GGACGACACGCAGTTCGTGAGGTTCGACAGCGACGCCGCGAGTCCGAGAGAGGAGCCGC
GGGCGCCGTGGATAGAGCAGGAGGGGCCGGAGTATTGGGACCGGAACACACAGATCTTCA
AGACCAACACACAGACTGACCGAGAGAGCCTGCGGAACCTGCGCGGCTACTACAACCAGA
GCGAGGCCGGGTCTCACACCCTCCAGAGCATGTACGGCTGCGACGTGGGGCCGGACGGG
CGCCTCCTCCGCGGGCATAACCAGTACGCCTACGACGGCAAGGATTACATCGCCCTGAACG
AGGACCTGCGCTCCTGGACCGCGGCGGACACCGCGGCTCAGATCACCCAGCGCAAGTGG
GAGGCGGCCCGTGTGGCGGAGCAGGACAGAGCCTACCTGGAGGGCACGTGCGTGGAGTG
GCTCCGCAGATACCTGGAGAACGGGAAGGACACGCTGGAGCGCGCGGACCCCCCAAAGAC
ACACGTGACCCACCACCCCATCTCTGACCATGAGGCCACCCTGAGGTGCTGGGCCCTGGG
CTTCTACCCTGCGGAGATCACACTGACCTGGCAGCGGGATGGCGAGGACCAAACTCAGGA
CACTGCGCTTGTGGAGACCAGACCAGCAGGAGATAGAACCTTCCAGAAGTGGGCAGCTGTG
GTGGTGCCTTCTGGAGAAGAGCAGAGATACACATGCCATGTACAGCATGAGGGGCTGCCGA
AGCCCCTCACCCTGAGATGGGAGGGAGGTTCCGGCGGTCTGGTTCCGCGTGGCTCGTTAA
CTGATACACTCCAAGCGGAGACAGATCAACTTGAAGACGAGAAGTCTGCGTTGCAGANCGA
GATTGCCNATCTACTGAAAGAGAAGGAAAAAACTGGANTTCATCCNGNNNGCCCATTAAAAG
CTTGAANTNCCGATCCGGCNGCTAACAAANCCCNAAAGGNNGCNNANNNGGGNNNCNNCC
NNCNNNNNNANCCAATNACNANNNANNNNCCCNNNNGNGGGNNNNTNN 
 
>B82291-T7-Term 
ttTcggGCTTTGTTAGCAGCCGGATCGGAATTCAAGCTTTTAATGGGCGGccAGGATGAACtCca
GTTTTTCCTTCTCTTTCAGTAGATTGGCAATCTCGGTCTGCAACGCAGACTTCTCGTCTTCAA
GTTGATCTGTCTCCGCTTGGAGTGTATCAGTTAACGAGCCACGCGGAACCAGACCGCCGGA
ACCTCCCTCCCATCTCAGGGTGAGGGGCTTCGGCAGCCCCTCATGCTGTACATGGCATGTG
TATCTCTGCTCTTCTCCAGAAGGCACCACCACAGCTGCCCACTTCTGGAAGGTTCTATCTCC
TGCTGGTCTGGTCTCCACAAGCGCAGTGTCCTGAGTTTGGTCCTCGCCATCCCGCTGCCAG
GTCAGTGTGATCTCCGCAGGGTAGAAGCCCAGGGCCCAGCACCTCAGGGTGGCCTCATGG
TCAGAGATGGGGTGGTGGGTCACGTGTGTCTTTGGGGGGTCCGCGCGCTCCAGCGTGTCC
TTCCCGTTCTCCAGGTATCTGCGGAGCCACTCCACGCACGTGCCCTCCAGGTAGGCTCTGT
CCTGCTCCGCCACACGGGCCGCCTCCCACTTGCGCTGGGTGATCTGAGCCGCGGTGTCCG
CCGCGGTCCAGGAGCGCAGGTCCTCGTTCAGGGCGATGTAATCCTTGCCGTCGTAGGCGT
ACTGGTTATGCCCGCGGAGGAGGCGCCCGTCCGGCCCCACGTCGCAGCCGTACATGCTCT
GGAGGGTGTGAGACCCGGCCTCGCTCTGGTTGTAGTAGCCGCGCAGGTTCCGCAGGCTCT
CTCGGTCAGTCTGTGTGTTGGTCTTGAAGATCTGTGTGTTCCGGTCCCAATACTCCGGCCCC
TCCTGCTCTATCCACGGCGCCCGCGGCTCCTCTCTCGGACTCGCGNNGTCGCTGTCGAACC
TCACGAACTGCGTGTCGTCCACGTAGCCCACTGAGATGAAGCGGGGCTCCCCGCGGCCGG
GNCGGGACATGGNNGGNGNCGAAATACCTCATGGNNNGGGATCCCATATGNATATCTTNCT
TTCTTAAAGNTNAAAACAAAAATTTATTTTCNANNNNNNAANCCNNNNNNNGNNNNNCCCCN
NNNTANNGNNNNNNNNNNTNNATTTTTNNNNNNNNNGGGNNAANNNNNA 
 
 31 
>b2mm1-T7 
tctagAataaTTTTgtTGAATTCGAGCTCGGTACCCGGGGATCCTAAGGAGGATATTAAAATGATC
CAGCGTACTCCAAAGATTCAGGTTTACTCACGTCATCCAGCAGAGAATGGAAAGTCAAATTT
CCTGAATTGCTATGTGTCTGGGTTTCATCCATCCGACATTGAAGTTGACTTACTGAAGAATGG
AGAGAGAATTGAAAAAGTGGAGCATTCAGACTTGTCTTTCAGCGCGGACTTGTCTTTCAGCG
CGGACTGGTCTTTCTATCTCTTGTACTACACTGAATTCACCCCCACTGAAAAAGATGAGTATG
CCTGCCGTGTGAACCATGTGACTTTGTCACAGCCCAAGATAGTTAAGTGGGATCGAGACATG
TAAAAGCTTGGCTGTTTTGGCGGATGAGAGAAGATTTTCAGCCTGATACAGATTAAATCAGA
ACGCAGAAGCGGTCTGATAAAACAGAATTTGCCTGGCGGCAGTAGCGCGGNGGTCCCACCT
GACCCCATGCCGAACTCAGAAGTGAAACGCCGTANCGCCGATGGTAGTGTGGGGTCTCCC
CATGCGAGTGTNGGGAACCGNCNNNNNTCNTATAAAANGAAAGGCTCNGTCGAAAGANTGG
NCCTTTCGATTTNTNTNTTGTTTTTCTNTTTNTNNNNTTTGNNTNNNN 
 
>b2mm1-pPLM4 
CTcgatcCacTTaacTATCTTGGGCTGTGACAAAGTCACATGGTTCACACGGCAGGCATACTCaT
CTTTTTCAGTGGGGGTGAATTCAGTGTAGTACAAGAGATAGAAAGACCAGTCCGCGCTGAAA
GACAAGTCCGCGCTGAAAGACAAGTCTGAATGCTCCACTTTTTCAATTCTCTCTCCATTCTTC
AGTAAGTCAACTTCAATGTCGGATGGATGAAACCCAGACACATAGCAATTCAGGAAATTTGA
CTTTCCATTCTCTGCTGGATGACGTGAGTAAACCTGAATCTTTGGAGTACGCTGGATCATTTT
AATATCCTCCTTAGGATCCCCGGGTACCGAGCTCGAATTCAACAAAATTATTTCTAGAGGGA
AACCGTTGTGGTCTCCCTATAGTGAGTCGTATTAATTTCGCAGCTGGCGTAATAGCGAAGAG
GCCCGCACCGATCGCCCTTCCCAACAGTTGCGCAGCCTGAATGGCGAATGGACGCGCCCT
GTAGCGGCGCATTAAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTG
CCAGCGCCCTAGCGCCCGCTCCTTTCGCTTTCTTCCCTtCCTTTCTCGCCACGTTCGCCGGC
TTTCCCCGTCAAGCT 
